with the objective of evaluating shortened therapeutic outlines effective in vivax malaria treatment, we accomplished an open, prospective study allocating 234 patients with vivax malaria distributed at random into eight therapeutic groups. Six groups used oral arthemisin as blood esquizonticide at different doses for one day and the other two groups received chloroquine in a single dose. The primaquine was used as a hypnozoiticide in all groups. They received a daily dose of 30mg in the course of five or seven days in all groups. The clearance of parasitaemia in patients treated with arthemisin (independent of dosage) was faster than the chloroquine group (p <0.01). Cure was acheived in 92.3% and 80.2%, in patients treated with primaquine for seven or five days, respectively (p=0.0372).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Guillain-Barré syndrome following falciparum malaria infection: a case report.
BMC Neurol
January 2025
Department of Radiology, School of Medicine, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.
Background: Malaria is an infectious disease caused by Plasmodium parasites, transmitted to humans by infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. vivax, P.
View Article and Find Full Text PDFYAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates.
Sci Rep
January 2025
Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-University of Barcelona), Rosselló 149-153, Barcelona, 08036, Spain.
We recently characterized the potent antiplasmodial activity of the aggregated protein dye YAT2150, whose presumed mode of action is the inhibition of protein aggregation in the malaria parasite. Using single-dose and ramping methods, assays were done to select Plasmodium falciparum parasites resistant to YAT2150 concentrations ranging from 3× to 0.25× the in vitro IC of the compound (in the two-digit nM range) and performed a cross-resistance assessment in P.
View Article and Find Full Text PDFAtypical memory B cells from natural malaria infection produced broadly neutralizing antibodies against Plasmodium vivax variants.
PLoS Pathog
January 2025
Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
Expansion of atypical memory B cells (aMBCs) was demonstrated in malaria-exposed individuals. To date, the generation of P. vivax-specific aMBCs and their function in protective humoral immune responses is unknown.
View Article and Find Full Text PDFMolecular epidemiology and genetic diversity of disappearing Plasmodium vivax in southern Thailand.
Sci Rep
January 2025
Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
The evolution of genetic diversity and population structure of Plasmodium vivax as malaria elimination approaches remains unclear. This study analyzed the genetic variation and molecular epidemiology of P. vivax from Yala Province in southern Thailand, an area in the pre-elimination phase.
View Article and Find Full Text PDFRecent Trends and Perspectives on Malaria Relapse: A Mini Review.
J Vector Borne Dis
January 2025
ICMR-National Institute of Malaria Research (NIMR) Field Unit, Nadiad, Gujarat, India.
Worldwide elimination of malaria remains a challenge yet to be accomplished, and the domain of malaria relapse equally remains obtuse. Yet sophisticated cell culture and screening techniques and animal models are being constructed and molecular regulations are discovered in this intriguing discipline. An elaborate understanding of these schemes is mandatory to conceive effective therapeutic strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!